4//SEC Filing
Audia James E 4
Accession 0001562180-21-004979
CIK 0001434418other
Filed
Jul 18, 8:00 PM ET
Accepted
Jul 19, 5:29 PM ET
Size
28.8 KB
Accession
0001562180-21-004979
Insider Transaction Report
Form 4
Audia James E
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2021-07-15−2,384→ 0 totalExercise: $5.51→ Common Stock (2,384 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-07-15−11,626→ 0 totalExercise: $4.08→ Common Stock (11,626 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-07-15−13,171→ 0 totalExercise: $9.12→ Common Stock (13,171 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-07-15−9,083→ 0 totalExercise: $7.60→ Common Stock (9,083 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-07-15−24,604→ 0 totalExercise: $5.62→ Common Stock (24,604 underlying) - Disposition to Issuer
Stock Options (Right to buy)
2021-07-15−13,171→ 0 totalExercise: $37.52→ Common Stock (13,171 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-07-15−8,175→ 0 totalExercise: $11.50→ Common Stock (8,175 underlying) - Disposition to Issuer
Common Stock
2021-07-15−25,434→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2021-07-15−13,171→ 0 totalExercise: $33.57→ Common Stock (13,171 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-07-15−1,277→ 0 totalExercise: $7.60→ Common Stock (1,277 underlying) - Disposition to Issuer
Stock Option (right to buy)
2021-07-15−9,083→ 0 totalExercise: $5.51→ Common Stock (9,803 underlying)
Footnotes (2)
- [F1]This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
- [F2]This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Documents
Issuer
CONSTELLATION PHARMACEUTICALS INC
CIK 0001434418
Entity typeother
Related Parties
1- filerCIK 0001746115
Filing Metadata
- Form type
- 4
- Filed
- Jul 18, 8:00 PM ET
- Accepted
- Jul 19, 5:29 PM ET
- Size
- 28.8 KB